Xiaogan Wang

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma

Hui Yu, Xing Wang, Jiao Li et al. · Molecular Therapy — Oncolytics · 2021 · 46 citations · Full text

Medicine, Oncology, Pharmacology +15

ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma

Yalu Liu, Xiaogan Wang, Lijuan Deng et al. · Cancer Cell International · 2019 · 40 citations · Full text

Life Sciences, Immunology, Oncology +15

Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients

Wenhui Cao, Xiaogan Wang, Lucien Frappart et al. · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · 2007 · 36 citations

Life Sciences, Genetics, Molecular Genetics +13

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma

Yizi He, Jiao Li, Ning Ding et al. · Journal of Experimental & Clinical Cancer Research · 2019 · 34 citations · Full text

Medicine, Oncology, Pharmacology +14

The mTOR kinase inhibitor everolimus synergistically enhances the anti‐tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS‐123 on Mantle cell lymphoma

Jiao Li, Xiaogan Wang, Yan Xie et al. · International Journal of Cancer · 2017 · 29 citations · Full text

Medicine, Oncology, Pharmacology +17